NMN
β-Nicotinamide Mononucleotide · β-NMN · Nicotinamide β-riboside 5′-monophosphate
Last updated
At a glance
Overview
NMN has become the default NAD⁺ precursor for physique-focused users who want a clean daily baseline for recovery, endurance, and metabolic health. It's not a body-recomp driver and nobody should pretend otherwise — but as a support compound layered into a TRT protocol, a blast, or a looksmaxxing longevity stack, it does real work: restoring the NAD⁺ pool that declines with age, heavy training loads, and the metabolic demands of running gear.
The mechanism is simple and well-characterized. NMN converts to NAD⁺ in a single enzymatic step, feeding sirtuin activity, mitochondrial throughput, and DNA-repair machinery. Human RCTs back the core claim — whole-blood NAD⁺ rises dose-dependently, insulin sensitivity improves in prediabetic subjects, and aerobic capacity ticks up in older adults. What you won't get is the rodent-scale longevity miracle the marketing implied five years ago; what you will get is a measurable floor under recovery, endurance, and metabolic efficiency.
"Supplementation with NMN significantly increased whole-blood NAD⁺ concentrations in a dose-dependent manner, with the 600 mg group achieving the largest increase and improvements in 6-min walk distance and SF-36 score." — Liu et al., GeroScience 2023
Below we cover the evidence-based NMN dosage ladder (250–900 mg, where the plateau actually sits), the NMN protocol for daily longevity use versus on-cycle NAD⁺ support, what the human trials really show, manageable NMN side effects and the TMG methylation fix, plus how to build an NMN stack that complements AAS, peptides, or a pure longevity regimen without wasting money on sublingual gimmicks.
How NMN works
NMN is a direct biosynthetic precursor to NAD⁺, the redox cofactor that every mitochondrion in your body needs to run oxidative phosphorylation and that every sirtuin needs to do its job. NAD⁺ levels decline ~50% between age 20 and 60, and they drop further under the kind of metabolic load that heavy training, high-dose AAS, and aggressive cutting create. NMN is one step away from NAD⁺ — a single enzymatic reaction (via the NMNAT family of adenylyltransferases) converts it to the active cofactor.
NAD⁺ Restoration via the Salvage Pathway#
Once inside the cell, NMN is adenylylated by NMNAT1/2/3 to produce NAD⁺ directly. This bypasses the slower de novo pathway from tryptophan and tops up the salvage pool that chronic PARP and CD38 activity keeps draining. The practical output: more substrate for mitochondrial ETC complexes, better β-oxidation, and better recovery between training sessions.
"NMN is a key NAD⁺ intermediate that is rapidly converted to NAD⁺ in cells, thereby helping restore cellular NAD⁺ pools that decrease during aging and metabolic stress." — Yoshino J, Baur JA, Imai S. Cell Metabolism, 2018
Cellular Uptake — Slc12a8 and the NR Detour#
How NMN actually gets into cells was controversial until Grozio et al. identified a dedicated transporter in the small intestine. This matters because it explains why oral NMN works without first being cleaved to nicotinamide riboside (NR) — you're not paying for an inferior precursor dressed up in phosphate.
"Here we identify and characterize Slc12a8 as a specific NMN transporter, clarifying how orally delivered NMN can directly elevate NAD⁺ biosynthesis in tissue." — Grozio A, Mills KF, Yoshino J, et al. Nature Metabolism, 2019
At higher oral doses, a second route — dephosphorylation to NR at the brush border, transport via equilibrative nucleoside transporters, then re-phosphorylation intracellularly by NRK1/2 — probably becomes dominant. Either way, the endpoint is tissue NAD⁺.
Sirtuin Activation and Mitochondrial Biogenesis#
NAD⁺ is the rate-limiting substrate for SIRT1, SIRT3, and SIRT6 — deacetylases that regulate PGC-1α (mitochondrial biogenesis), FOXO3 (stress resistance), and p53 (DNA damage response). Raising the NAD⁺ pool lets these enzymes actually run. For a physique-focused user this shows up as better aerobic capacity, better work-capacity recovery, and — in the subset of users running heavy conditioning — measurable endurance gains. The Liu 2023 RCT picked up a statistically meaningful improvement in 6-minute walk distance at 600 mg/day that tracks this mechanism.
"Supplementation with NMN significantly increased whole-blood NAD⁺ concentrations in a dose-dependent manner, with the 600 mg group achieving the largest increase and improvements in 6-min walk distance and SF-36 score." — Liu Y, Guo Y, et al. GeroScience, 2023
Muscle Insulin Sensitivity and Glucose Handling#
The most concrete physique-relevant human finding to date: 10 weeks of 250 mg/day NMN improved skeletal muscle insulin sensitivity by roughly 25% in prediabetic postmenopausal women, with corresponding changes in muscle gene-expression signatures related to remodelling. For anyone running a recomp, lean-bulking on a modest calorie surplus, or blunting the insulin resistance that comes with heavy oral cycles, better muscle glucose uptake is a useful knob to turn.
"10 weeks of oral NMN supplementation increased muscle insulin sensitivity by approximately 25% in prediabetic postmenopausal women." — Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021
Neuromuscular and Peripheral Nerve Effects#
NAD⁺ supports axonal integrity via the SARM1/NMNAT2 axis — NMNAT2 loss drives Wallerian-style axon degeneration, and NMN feeding preserves it. In older diabetic patients, 24 weeks of NMN improved nerve conduction velocity and grip strength, suggesting the mechanism translates to functional output and not just bloodwork.
"NMN supplementation significantly improved nerve conduction parameters and increased grip strength after 24 weeks in older diabetic patients." — Akasaka H, Nakagami H, Sugimoto K, et al. Geriatrics & Gerontology International, 2023
The honest framing: NMN is not a body-recomp driver, and the effect sizes in humans are modest compared to the mouse literature that got everyone excited. What it does do — reliably, at reasonable doses — is restore a cofactor pool that falls with age and metabolic stress, and that restoration shows up as slightly better insulin sensitivity, slightly better endurance, slightly better recovery, and a plausible longevity bet. Treat it as a baseline support compound, not a performance drug.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 250–500 mg | Once daily | Documented entry-level range |
| Mid | 500–750 mg | Once daily | Most commonly studied range |
| High | 750–1000 mg | Once daily | AM on empty stomach is standard. Split AM + midday at doses >600 mg to smooth the NAD+ curve. Avoid late-evening dosing — NAD+ rise can be stimulating. |
Cycle length & outcomes
Documented cycle
8–52 weeks
Plateau after
12 wks
Cycle Length & Cadence#
NMN is a continuous-use longevity supplement, not a cycled hormonal compound. It doesn't suppress any endogenous axis, doesn't require PCT, and doesn't benefit from on/off cycling the way peptides or AAS do. That said, physique-focused users tend to run it in defined blocks tied to training phases or bloodwork cycles.
Goal-Based Protocols#
| Goal | Cycle Length | Daily Dose | Notes |
|---|---|---|---|
| Baseline longevity / daily driver | 12+ weeks, continuous | 250–500 mg AM | Minimum effective dose per Yoshino 2021 |
| Recomp / insulin sensitivity | 10–12 weeks | 250–500 mg AM | Pair with resistance training + protein-forward diet |
| Endurance / conditioning block | 8–12 weeks | 600 mg (split AM + pre-workout) | 600 mg hit the functional sweet spot in Liu 2023 |
| On-cycle NAD⁺ support (AAS/GH) | Run alongside cycle + 4 weeks past | 500–1000 mg (split AM + pre-workout) | Add 500–1000 mg TMG to cover methylation |
| High-end longevity stack | 6–12 month blocks | 750–1000 mg (split AM + midday) | Above 900 mg shows no extra NAD⁺ rise in trials |
| Older / perimenopausal recomp | 24+ weeks | 250–500 mg AM | Akasaka 2023 protocol: 24 wk @ 250 mg improved grip + nerve conduction |
Onset & Time-to-Effect#
NMN doesn't work on the acute-dose timescale of a stimulant or a pump product. It works by rebuilding the NAD⁺ pool, which takes weeks.
- Day 1–14: Whole-blood NAD⁺ rises measurably. Most users feel nothing yet.
- Week 2–4: Subjective energy, training recovery, and sleep quality tend to improve. Steady-state NAD⁺ elevation is approaching.
- Week 8–12: Functional endpoints show up in trials — insulin sensitivity (Yoshino 2021), 6-minute walk distance (Liu 2023), grip strength (Akasaka 2023).
- Week 12+: Plateau. Running longer at the same dose gives diminishing returns; this is where most people either hold the dose or stop re-evaluating.
"Supplementation with NMN significantly increased whole-blood NAD⁺ concentrations in a dose-dependent manner, with the 600 mg group achieving the largest increase and improvements in 6-min walk distance and SF-36 score." — Liu et al., GeroScience (2023)
"10 weeks of oral NMN supplementation increased muscle insulin sensitivity by approximately 25% in prediabetic postmenopausal women." — Yoshino et al., Science (2021)
Loading & Tapering#
No loading phase is needed. NMN doesn't have a loading-dose PK profile like creatine — you start at your target dose on day one and let the NAD⁺ pool climb over the first 2–4 weeks. Frontloading with 2 g/day for a week produces no data-supported advantage.
No taper is needed on the way down. There's no rebound, no suppression to recover from, no HPTA crash. You can stop cold. Tissue NAD⁺ will gradually drift back toward baseline over several weeks once you discontinue.
On-Cycle Bloodwork#
NMN itself doesn't move standard bloodwork, so there's no required cadence the way there is for AAS. What longevity-focused users do track:
- Intracellular NAD⁺ panel (Jinfiniti or equivalent) at baseline, week 4, and quarterly. If NAD⁺ isn't elevated by week 4, either the product is underdosed (common with cheap powder — demand an HPLC COA ≥99%), or you're a hyper-clearer and need to split the dose or raise it.
- Standard metabolic panel (fasting glucose, HbA1c, lipids) every 3–6 months if you're running it for the insulin-sensitivity angle.
- Homocysteine if you're at high dose without TMG — elevated homocysteine is the first sign methylation is getting taxed.
Practical Cadence Notes#
- Timing: AM, empty stomach. Doses above ~600 mg are worth splitting AM + midday to smooth the NAD⁺ curve and avoid the "wired" feeling some users report.
- Avoid late-evening dosing. NAD⁺ rise is mildly stimulating and can interfere with sleep onset.
- Run it through a cycle and 4 weeks past. When NMN is coadministered with a blast, it is typically continued through the final pin — recovery is when NAD⁺ demand is highest.
- Don't expect aesthetic changes. NMN is a floor-raiser: better recovery, better endurance throughput, better metabolic flexibility. It's not a recomp driver on its own. Judge it on training quality and bloodwork, not the mirror.
Risks & mistakes
Common (most users)#
- Mild GI discomfort, nausea, or loose stool — almost exclusively at doses >1 g/day. Drop back to 500 mg, split AM + midday, and take with a small amount of food if empty-stomach dosing bothers you.
- Methylation headaches — low-grade frontal headache or mental fog in week 1–2, driven by methyl-group draw as NAM is cleared via NNMT. Add 500–1,000 mg TMG (betaine) daily; ensure adequate B12, folate, and choline. Resolves within a few days.
- Late-day stimulation / insomnia — the NAD⁺ rise is energizing for some users. Keep dosing to AM; if splitting, take the second dose no later than early afternoon.
- Mild, transient flushing — much less than niacin (NMN doesn't activate GPR109A the way nicotinic acid does). No action needed; fades with continued use.
Uncommon (dose-dependent or individual)#
- Persistent GI upset at >1 g/day — back down to the 500–750 mg range. The Liu 2023 dose-escalation showed no added NAD⁺ benefit at 900 mg vs 600 mg, so pushing higher rarely pays off.
"Supplementation with NMN significantly increased whole-blood NAD⁺ concentrations in a dose-dependent manner, with the 600 mg group achieving the largest increase and improvements in 6-min walk distance and SF-36 score." — Liu et al., GeroScience (2023)
- Palpitations or mild anxiety — occasional at high split doses, usually in people already on stimulants or high caffeine. Drop dose and consolidate to once-daily AM.
- Mystery headaches that TMG doesn't fix — check homocysteine and B-vitamin status on routine bloodwork. Chronic high-dose NAD⁺ precursor use raises methylation turnover.
- "Nothing is happening" — some users are hyper-clearers. Confirm the product isn't underdosed (demand an HPLC COA ≥99 %), split AM + midday, and consider an intracellular NAD⁺ panel (Jinfiniti or similar) at week 4–6 to confirm the compound is actually moving blood NAD⁺.
Rare but serious#
- No serious adverse events have been reported in published human trials at daily doses up to 900 mg for 60 days or 250 mg for 24 weeks (Liu 2023; Akasaka 2023).
- Theoretical tumor-fueling concern — NAD⁺ is consumed by rapidly proliferating cells, and preclinical work has raised the possibility that raising NAD⁺ could support existing tumor metabolism. No human signal exists, but the concern is mechanistically plausible enough to respect. Stop immediately if an unexplained mass, persistent lymphadenopathy, or unexpected weight loss shows up, and get it worked up.
Hard contraindications#
- Active malignancy or recent cancer treatment — do not run NMN. The NAD⁺-and-tumor question is unresolved, and a longevity supplement is not worth the bet against a proliferating cell population.
- Pregnancy and lactation — no safety data. Skip it.
- Known NMN/NR allergy or hypersensitivity reaction — rare, but a reason to stop.
NMN does not interact meaningfully with AAS, SARMs, peptides, PDE5 inhibitors, thyroid hormone, insulin, or GH. It is not hepatotoxic, not nephrotoxic in humans at studied doses, and does not affect blood pressure or lipids.
Gender, fertility, and PCT notes#
NMN is non-hormonal and has no PCT implications — it does not suppress the HPTA, does not aromatize, and does not affect SHBG, prolactin, or estrogen. It is safe for women at the same doses used in men; the pivotal insulin-sensitivity trial was run at 250 mg/day in postmenopausal women.
"10 weeks of oral NMN supplementation increased muscle insulin sensitivity by approximately 25% in prediabetic postmenopausal women." — Yoshino et al., Science (2021)
No known effect on semen parameters, menstrual cycle, or fertility in either direction. For the recomp-focused reader running AAS, SARMs, or a GH/insulin stack, NMN is one of the few ancillaries you can run continuously year-round without worrying about cycling it off.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.08 | ×1.04 | ×1.20 | |
| synergistic | ×1.07 | ×1.10 | ×1.18 | |
| synergistic | ×1.05 | ×1.10 | ×1.15 |
Featured in stacks1 curated protocol include NMN
FAQ — NMN
Research & citations
5 studies cited on this page.
Conclusion
NMN is a cornerstone NAD+ precursor for anyone serious about longevity, metabolic support, or recovery — simple to run and well-tolerated if you dial in the basics.
Key takeaways:
- Standard dose: 250–600 mg daily (oral, AM, empty stomach); 500 mg is the sweet spot for most
- Split dose AM + midday if running >600 mg to smooth NAD+ curve and avoid late-day stimulation
- Stack with 500–1,000 mg TMG (betaine) at higher doses to prevent methylation-related headaches
- Cycle length: 8–52 weeks; evidence supports continuous daily use
- Expect subtle increases in endurance, recovery, and insulin sensitivity over 2–12 weeks — not direct muscle gain
- Clean safety profile at clinical doses; avoid if you have active malignancy or are pregnant/lactating
Bottom line: NMN is a rigorously trialed base-layer longevity compound, easy to plug into a stack for NAD+ support, endurance, or active recovery — just don't expect AAS-tier physique changes.